No Prescription |
 |
 | ||
|
ARMOTRAZ Arimidex |
|
| ||
No Prescription » Prescription Drugs 2 » ARMOTRAZ Arimidex Armotraz is used for: Treating breast cancer in women who have been through menopause including women with disease progression after tamoxifen therapy. Anastrozole is a first-line treatment of breast cancer in postmenopausal women. It slows the growth of advanced cancer within the breast and cancer that has spread to other parts of the body. Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole. Buy ARMOTRAZ Arimidex and other Prescription Drugs 2 products online at Medstore. Buy Online at Medstore - Click Here!
About ARMOTRAZ Arimidex: Product Type: Prescription Drugs 2 ARMOTRAZ ( Arimidex Generic Anastrazole ) ARMOTRAZ (Arimidex Generic Anastrazole) Arimidex Generic Anastrazole 1mg 30 Tablets 60 Tablets 90 Tablets Arimidex Generic Anastrazole ARMOTRAZ
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
